Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Stock Information for Niagen Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Niagen Bioscience Inc.

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus(TM)
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience to Present at the 38th Annual ROTH Conference
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud(TM), From Tru Niagen Powered by Patented Niagen®
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.